NCT07539090PHASE1RecruitingAccepts Healthy Volunteers
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
Deciphera Pharmaceuticals, LLC
Start Date
6/5/2026
Completion Date
8/1/2026
Summary
The main purpose of this study is to determine the effect of vimseltinib on pharmacokinetics of combined oral contraceptive (COC) (ethinyl estradiol/levonorgestrel) in healthy female participants. This study will last approximately 35 days.
Eligibility Criteria
Age Range: 18 years to 55 years
Inclusion Criteria:
1. Participants are in good general health, as required by the protocol and as determined by Principal Investigator.
2. Body mass index (BMI) from greater than or equal to (≥) 18.5 to less than or equal to ≤ 30 kilogram per square meter (kg/m\^2).
3. Adequate organ function, blood and urine tests, as required by the protocol and as determined by Principal Investigator.
Exclusion Criteria:
1. History or presence of clinically significant diseases of the neurological, dermatological, renal, hepatic, gastrointestinal, cardiovascular, or musculoskeletal systems or history or presence of clinically significant psychiatric, immunological, endocrine, or metabolic disease as determined by Principal Investigator.
2. Unwilling or unable to comply with the requirements of the protocol.
3. Determined by Principal Investigator to be unsuitable to participate in the study for any other reason.
Interventions
DRUG
Vimseltinib
DRUG
Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Conditions
Healthy Participants
Locations
Nucleus Network
Saint Paul, Minnesota 55114
United States